Covance and Lilly Honored with Alliance Excellence Award
Covance Inc. and Eli Lilly and Company were recently honored by the Association of Strategic Alliance Professionals (ASAP) with a 2014 Alliance Excellence Award for a long established alliance. The two companies were recognised for their transformative collaboration that has infused greater efficiency and quality into the drug development process and enabled new medicines to advance to market sooner.
"Our awards committee was impressed by the many ways in which this groundbreaking alliance continues to evolve — utilising best practices in alliance management, harnessing technologies, building a collaborative culture and investing in process innovation," said Michael Leonetti, ASAP president and CEO. "We also commend this partnership's willingness to share their knowledge and experiences, and further contribute to the advance of the alliance management profession."
As a result of this unique alliance, Covance and Lilly completed more than 11,000 studies in support of discovery research and more than 500 toxicology studies supporting nearly 50 different molecules. More than 800 studies have been conducted spanning late-stage development, including clinical, central laboratories, genomics, biomarkers and companion diagnostics. Joint training programmes ensure that the companies maintain leading edge competencies given the highly competitive global pharmaceutical market.
"We are 5 years strong into our industry-pioneering alliance with Covance, designed to support the transformation of our R&D model," commented Andrew Dahlem, PhD, Vice President, Chief Operating Officer, Lilly Research Laboratories (LRL) and LRL Europe. "Working together, we have improved research and development efficiencies, reduced costs, and accelerated drug development timelines by as much as 50%. Ultimately, we are measuring success against our most important goal — to speed quality, innovative medicines to patients."
In 2008, as part of the original agreement, Lilly transferred their Greenfield, Ind. facility and approximately 250 employees to Covance. With the addition of 300 new jobs and seven new services since, the Covance Greenfield site now supports development innovation for more than 150 biopharmaceutical companies, in addition to Lilly, with expanded services that include biomarkers, biologic compounds, bioanalysis, and a full biorepository to help companies efficiently store biosamples. The Greenfield operations combined with the multiplied effects of those operations involving other companies are estimated to have added 564 jobs, $35.7 million in wages annually, and $102.4 million in annual output to the state of Indiana, according to a report by Crowe Horwath.
"Receiving this award is not only an important endorsement of our business strategy, it also reflects the dedication and expertise of the employees who have been the driving force behind this strategic partnership," added John Watson, President, Strategic Partnering, and Chief Commercial Officer, Covance. "As a result of our connected and forward-thinking partnership, the alliance continues to exceed expectations and deliver enormous value to both Lilly and Covance."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance